News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BeiGene Co.,Ltd Receives $5 Million Clinical Milestone Payment For Development Of BGB-283


5/5/2014 9:46:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEIJING--(BUSINESS WIRE)--BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company’s collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development. The milestone triggers a US$ 5 million payment from Merck to BeiGene.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com
Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES